The initially results of neoadjuvant chemoradiation followed by consolidation chemotherapy for stage II, III rectal cancer patients

  • Nguyễn Hải Hoàng Bệnh viện Ung bướu Nghệ An
  • Nguyễn Thị Nga Bệnh viện Ung bướu Nghệ An
  • Nguyễn Viết Bình Bệnh viện Ung bướu Nghệ An
  • Vũ Hồng Thăng Bệnh viện K

Main Article Content

Keywords

Rectal cancer, clinical complete response, total neoadjuvant therapy

Abstract

Objective: To evaluate the clinical complete response (cCR) and related factors in stage II-III rectal cancer patients treated with neoadjuvant chemoradiation followed by consolidation chemotherapy (total neoadjuvant therapy) before surgery. Subject and method: 36 rectal cancer patients at stage II-III underwent preoperative chemoradiationof 50.4Gy/28fx concurrent with Capecitabine 825mg/m2, twice a day × 5 days/week followed by 12-16 weeks consolidation chemotherapy of FOLFOX or CAPEOX from April 2022 to April 2023 at Nghe An Oncology Hospital. Treatment response were assessed at the time of 6-12 weeks and 18-24 weeks from the last day of radiotherapyby digital rectal examination, flexible rectoscopy, and pelvic MRI. The relationship between clinical factors and cCR was evaluated. Result: The cCR rates were 11.1% at 6-12 weeks and 36.1% at 18-24 weeks post radiotherapy. There were statistically significant differences in cCR rates among the following groups: tumor stage T2-3 (43.3%) versus T4 (0%), nodal stage N0 (100%) versus N1 (40%) and N2 (22.7%), scarbrous tumor (66.7%) versus ulcerated - scabrous tumor (20.8%), and tumor length ≤ 4cm (72.2%) versus > 4cm (0%) (p<0.05). Conclusion: The percentage of patients who achieved cCR at 18-24 weeks was higher than at 6-12 weeks after the end of radiotherapy. Tumors ≤ T3, lymph nodes N0, tumor length ≤ 4cm, scarbrous morphology had high cCR rates.

Article Details

References

1. Võ Văn Xuân, Nguyễn Đại Bình, Ngô Vĩ Dung (2012) Nghiên cứu áp dụng kỹ thuật xạ trị gia tốc tăng phân liều tiền phẫu kết hợp với phẫu thuật ung thư trực tràng. Tạp chí Ung thư học Việt Nam, Hội phòng chống Ung thư Việt Nam, số 2-2012, tr. 57-66.
2. Asoglu O, Beslen G, Vusal Aliyev et al (2022) Watch and wait strategy for rectal cancer: How long should we wait for a clinical complete response? Surg Technol Int 40: 130-139.
3. Gérard J-P, Chamorey E, Sophie G-B et al (2015) Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiother Oncol. 115(2): 246-252.
4. Glynne-Jones, L Wyrwicz, E Tiret et al (2017) Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28(4): 22-40.
5. Hupkens BJP, Martens MH et al (2018) Organ preservation in rectal cancer after chemoradiation: Should we extend the observation period in patients with a clinical near-complete response? Ann Surg Oncol 25: p197-203.
6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2020) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin: 1-41.
7. Joshua DI Ellenhorn CAC, a.L.R.C.e.a. (2006) Colon, rectal and anal cancers. 2006: Cancer management: a multidisciplinary approach. Oncology News International: 343-375.
8. Joshua Smith, Oliver S. Chow, Marc J. Gollub, et al (2015) Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total. BMC Cancer 767.
9. Michał Jankowski, Lucyna Pietrzak, Maciej Rupiński et al (2021) Watch-and-wait strategy in rectal cancer: Is there a tumour size limit? Results from two pooled prospective studies. Radiotherapy and Oncology 160: 229-235.
10. Petrelli F, Trevisan F, Cabiddu M et al (2016) Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: A meta-analysis of published studies. Ann Surg 263: 458-464.
11. Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF, Ribeiro U Jr, Cotti GC, Imperiale AR, Capareli FC, Chih Chen AT, Hoff PM, Cecconello I (2016) Pathologic complete response in rectal cancer: can we detect it? Lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer. Abdom Radiol (NY) 59(4): 255-263.
12. Shuang Liu, Jiang T, Xiao L et al (2021) Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. The Oncologist 26(9): 1555-1566.
13. Suwanthanma W, Kitudomrat S, Euanorasetr C (2021) Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment. Medicine 100(38).

Article Sidebar

PDF (Tiếng Việt)
Published
May 5, 2023
DOI: https://doi.org/10.52389/ydls.v18i0.1774
Issue
Volume 18 - Special Issue 5/2023: The Scientific Conference on Radiation Oncology, 2023
Section
Articles
How to Cite
HoàngN. H., NgaN. T., BìnhN. V., & ThăngV. H. (2023). The initially results of neoadjuvant chemoradiation followed by consolidation chemotherapy for stage II, III rectal cancer patients. Tạp Chí Y Dược lâm sàng 108, 18. https://doi.org/10.52389/ydls.v18i0.1774